Adipose‑derived mesenchymal stem cells attenuate cisplatin‑induced apoptosis in epithelial ovarian cancer cells

Wen,Yiping; Guo,Yan; Huang,Zaiju; Cai,Jing; Wang,Zehua

doi:10.3892/mmr.2017.7783

Adipose‑derived mesenchymal stem cells attenuate cisplatin‑induced apoptosis in epithelial ovarian cancer cells

Authors:
- Yiping Wen
- Yan Guo
- Zaiju Huang
- Jing Cai
- Zehua Wang
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China
Published online on: October 12, 2017 https://doi.org/10.3892/mmr.2017.7783
Pages: 9587-9592

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Environment-mediated drug resistance (EMDR) serves an important role in tumor chemotherapy resistance. Adipose‑derived mesenchymal stem cells (ADSC) are an important component of the tumor microenvironment. However, the role of ADSC in EMDR remains unclear. Therefore, in order to clarify whether ADSCs contribute to the cisplatin‑mediated apoptosis in epithelial ovarian cancer (EOC), the present study isolated ADSCs from the omentum of women with benign disease and collected the ADSC culture medium as conditioned medium. Subsequently, it was revealed that ADSCs decreased the sensitivity of EOC cells to cisplatin via an MTT assay. In addition, it was revealed that ADSCs may reduce cisplatin-induced apoptosis in EOC cells, as determined by Hoechst staining and flow cytometric analysis. Additionally, a lower level of cleaved caspase‑3 was observed, accompanied with decreased intracellular platinum accumulation in EOC cells indirectly co‑cultured with ADSCs. In conclusion, the findings of the present study suggested that ADSCs reduced cisplatin‑induced apoptosis and the intracellular level of platinum in EOC cells, which in turn resulted in cisplatin resistance. Therefore, ADSCs may serve as a therapeutic target for recurrent EOC.

View Figures

View References

1	Jayson GC, Kohn EC, Kitchener HC and Ledermann JA: Ovarian cancer. Lancet. 384:1376–1388. 2014. View Article : Google Scholar : PubMed/NCBI
2	Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, Colombo N, Fowler JM, Argenta PA, De Geest K, et al: Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: A Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 27:1419–1425. 2009. View Article : Google Scholar : PubMed/NCBI
3	Cannistra SA: Cancer of the ovary. N Engl J Med. 351:2519–2529. 2004. View Article : Google Scholar : PubMed/NCBI
4	McMeekin DS, Tillmanns T, Chaudry T, Gold M, Johnson G, Walker J and Mannel R: Timing isn't everything: An analysis of when to start salvage chemotherapy in ovarian cancer. Gynecol Oncol. 95:157–164. 2004. View Article : Google Scholar : PubMed/NCBI
5	Ilmer M, Vykoukal J, Boiles A Recio, Coleman M and Alt E: Two sides of the same coin: Stem cells in cancer and regenerative medicine. FASEB J. 28:2748–2761. 2014. View Article : Google Scholar : PubMed/NCBI
6	Chan JK and Lam PY: Human mesenchymal stem cells and their paracrine factors for the treatment of brain tumors. Cancer Gene Ther. 20:539–543. 2013. View Article : Google Scholar : PubMed/NCBI
7	Dittmer J and Leyh B: Paracrine effects of stem cells in wound healing and cancer progression (Review). Int J Oncol. 44:1789–1798. 2014. View Article : Google Scholar : PubMed/NCBI
8	Ma S, Xie N, Li W, Yuan B, Shi Y and Wang Y: Immunobiology of mesenchymal stem cells. Cell Death Differ. 21:216–225. 2014. View Article : Google Scholar : PubMed/NCBI
9	Ghobadi F, Mehrabani D and Mehrabani G: Regenerative potential of endometrial stem cells: A mini review. World J Plast Surg. 4:3–8. 2015.PubMed/NCBI
10	Raja FA, Chopra N and Ledermann JA: Optimal first-line treatment in ovarian cancer. Ann Oncol. 23 Suppl 10:x118–x127. 2012. View Article : Google Scholar : PubMed/NCBI
11	Weidle UH, Birzele F, Kollmorgen G and Rueger R: Mechanisms and targets involved in dissemination of ovarian cancer. Cancer Genomics Proteomics. 13:407–423. 2016. View Article : Google Scholar : PubMed/NCBI
12	Baer PC: Adipose-derived mesenchymal stromal/stem cells: An update on their phenotype in vivo and in vitro. World J Stem Cells. 6:256–265. 2014. View Article : Google Scholar : PubMed/NCBI
13	Kang BJ, Lee SH, Kweon OK and Cho JY: Differentiation of canine adipose tissue-derived mesenchymal stem cells towards endothelial progenitor cells. Am J Vet Res. 75:685–691. 2014. View Article : Google Scholar : PubMed/NCBI
14	Minteer DM, Marra KG and Rubin JP: Adipose stem cells: Biology, safety, regulation, and regenerative potential. Clin Plast Surg. 42:169–179. 2015. View Article : Google Scholar : PubMed/NCBI
15	Arie AB, McNally L, Kapp DS and Teng NN: The omentum and omentectomy in epithelial ovarian cancer: A reappraisal: Part II-The role of omentectomy in the staging and treatment of apparent early stage epithelial ovarian cancer. Gynecol Oncol. 131:784–790. 2013. View Article : Google Scholar : PubMed/NCBI
16	Ben Arie A, McNally L, Kapp DS and Teng NN: The omentum and omentectomy in epithelial ovarian cancer: A reappraisal. Part I-Omental function and history of omentectomy. Gynecol Oncol. 131:780–783. 2013. View Article : Google Scholar : PubMed/NCBI
17	Chu Y, Tang H, Guo Y, Guo J, Huang B, Fang F, Cai J and Wang Z: Adipose-derived mesenchymal stem cells promote cell proliferation and invasion of epithelial ovarian cancer. Exp Cell Res. 337:16–27. 2015. View Article : Google Scholar : PubMed/NCBI
18	Xue Z, Wu X, Chen X, Liu Y, Wang X, Wu K, Nie Y and Fan D: Mesenchymal stem cells promote epithelial to mesenchymal transition and metastasis in gastric cancer though paracrine cues and close physical contact. J Cell Biochem. 116:618–627. 2015. View Article : Google Scholar : PubMed/NCBI
19	Meads MB, Gatenby RA and Dalton WS: Environment-mediated drug resistance: A major contributor to minimal residual disease. Nat Rev Cancer. 9:665–674. 2009. View Article : Google Scholar : PubMed/NCBI
20	Qi S and Wu D: Bone marrow-derived mesenchymal stem cells protect against cisplatin-induced acute kidney injury in rats by inhibiting cell apoptosis. Int J Mol Med. 32:1262–1272. 2013. View Article : Google Scholar : PubMed/NCBI
21	Zhou Y, Xu H, Xu W, Wang B, Wu H, Tao Y, Zhang B, Wang M, Mao F, Yan Y, et al: Exosomes released by human umbilical cord mesenchymal stem cells protect against cisplatin-induced renal oxidative stress and apoptosis in vivo and in vitro. Stem Cell Res Ther. 4:342013. View Article : Google Scholar : PubMed/NCBI
22	Guan J and Chen J: Mesenchymal stem cells in the tumor microenvironment. Biomed Rep. 1:517–521. 2013. View Article : Google Scholar : PubMed/NCBI
23	De Boeck A, Pauwels P, Hensen K, Rummens JL, Westbroek W, Hendrix A, Maynard D, Denys H, Lambein K, Braems G, et al: Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling. Gut. 62:550–560. 2013. View Article : Google Scholar : PubMed/NCBI
24	Roodhart JM, Daenen LG, Stigter EC, Prins HJ, Gerrits J, Houthuijzen JM, Gerritsen MG, Schipper HS, Backer MJ, van Amersfoort M, et al: Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids. Cancer Cell. 20:370–383. 2011. View Article : Google Scholar : PubMed/NCBI
25	Wei HJ, Zeng R, Lu JH, Lai WF, Chen WH, Liu HY, Chang YT and Deng WP: Adipose-derived stem cells promote tumor initiation and accelerate tumor growth by interleukin-6 production. Oncotarget. 6:7713–7726. 2015. View Article : Google Scholar : PubMed/NCBI
26	Xu L, Wang X, Wang J, Liu D, Wang Y, Huang Z and Tan H: Hypoxia-induced secretion of IL-10 from adipose-derived mesenchymal stem cell promotes growth and cancer stem cell properties of Burkitt lymphoma. Tumour Biol. 37:7835–7842. 2016. View Article : Google Scholar : PubMed/NCBI
27	Burger H, Loos WJ, Eechoute K, Verweij J, Mathijssen RH and Wiemer EA: Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist Updat. 14:22–34. 2011. View Article : Google Scholar : PubMed/NCBI